Delving into the Latest Updates on TD-0212 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

AT1R x CD10

Mechanism

AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), enkephalinase inhibitors(Neprilysin inhibitors)

Therapeutic Areas

Cardiovascular DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

Cardiovascular DiseasesKidney Diseases

Originator Organization

Innoviva, Inc.

Active Organization-

Inactive Organization

Theravance Biopharma, Inc.

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

Dual inhibition of angiotensin-converting enzyme (ACE) and neprilysin (NEP) by drugs such as omapatrilat produces superior antihypertensive efficacy relative to ACE inhibitors but is associated with a higher risk of life-threatening angioedema due to bradykinin elevations. We hypothesized that dual AT₁ (angiotensin II type 1 receptor) blockade and NEP inhibition with a single molecule would produce similar antihypertensive efficacy to omapatrilat without the risk of angioedema since ACE (the rate limiting enzyme in bradykinin metabolism) would remain uninhibited. Merging the structures of losartan (an AT₁ antagonist) and thiorphan (a NEP inhibitor) led to the discovery of a novel series of orally active, dual AT₁ antagonist/NEP inhibitors (ARNIs) exemplified by compound 35 (TD-0212). In models of renin-dependent and -independent hypertension, 35 produced blood pressure reductions similar to omapatrilat and combinations of AT₁ receptor antagonists and NEP inhibitors. Upper airway angioedema risk was assessed in a rat tracheal plasma extravasation (TPE) model. Unlike omapatrilat, 35 did not increase TPE at antihypertensive doses. Compound 35 therefore provides the enhanced activity of dual AT₁/NEP inhibition with a potentially lower risk of angioedema relative to dual ACE/NEP inhibition.

100 Deals associated with TD-0212

Login to view more data